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In addition to the JAK2 V617F mutation, somatic mutation in DNMT3A has been described in BCL-ABL1-
negative myeloproliferative neoplasms (MPNs). We have screened for DNMT3A exon 23 mutations in 130
adult Taiwanese patients with chronic phase myeloproliferative neoplasms. Only one somatic DNMT3A
R882H mutation was identiﬁed in one JAK2 V617F mutation-positive essential thrombocythemia patient
(1/91, 1%). Both mutations were detected in the CD34þ-, CD19þ-, peripheral blood mononuclear cell- and
granulocyte-enriched fractions, but were not detected in the CD3þ-enriched fraction by lineage analysis.
Our ﬁndings suggest that DNMT3A mutation is not prevalent in MPNs, and further study is needed to
clarify its role in the molecular pathogenesis of myeloproliferative neoplasms.
Copyright  2013, Taiwan Society of Geriatric Emergency & Critical Care Medicine. Published by Elsevier
Taiwan LLC. All rights reserved.1. Introduction
The BCL-ABL1-negative myeloproliferative neoplasms (MPNs),
including polycythemia vera (PV), essential thrombocythemia (ET)
and primarymyeloﬁbrosis (PMF), are clonal hematopoietic stem cell
disorders1. Following the identiﬁcation of JAK2 V617F mutation,
many novel somatic mutations have since been described in MPNs,
such as DNMT3A mutation1,2. DNMT3A encodes one of the two hu-
man de novoDNAmethyltransferases which catalyze the addition of
a methyl group to speciﬁc cytosine residues3. Recently, somatic
DNMT3A mutations were found in 4e22% patients with de novo
acutemyeloid leukemia (AML)4e6, andwere associatedwith shortervolvement in, within the past
ity with a ﬁnancial interest in
rials discussed in the manu-
nsultancies, honoraria, stock
atents received or pending,
related to the material in the
of Hematology and Oncology,
Hospital, Number 92, Section
).
iwan Society of Geriatric Emergenoverall survival5e7. Many of the reported DNMT3A mutations were
heterozygous missense mutations affecting the methyltransferase
domain,with ahotspot at codonR882 in exon23. In addition toAML,
DNMT3A mutations have also been identiﬁed in MPNs, myelodys-
plastic syndrome and T-cell lymphoma8e12. In this study, we sought
to screen for DNMT3A mutations in a cohort of Taiwanese patients
with chronic phase MPNs. Analysis of lineage speciﬁcity was per-
formed for the patient who harbored the DNMT3Amutation.2. Patients and methods
This study was approved by the Institutional Review Board of
the Mackay Memorial Hospital. Overall, 130 adult patients with
MPN (35 PV, 91 ET, 4 PMF) were enrolled in our study, and all pa-
tients provided written informed consent. Genomic DNA derived
from bone marrow granulocytes, peripheral whole blood, periph-
eral blood granulocytes (PBGCs) or peripheral blood mononuclear
cells (PBMCs) were used for the screening of mutations in DNMT3A
exon 23 spanning codons 866e912 [GenBank:NM_022552.2] by
nucleotide sequencing. The mutational status of JAK2 V617F [Gen-
Bank:NM_004972.3] was determined by allele-speciﬁc polymerase
chain reaction as described13. In addition, the entire JAK2 exon 12,cy & Critical Care Medicine. Published by Elsevier Taiwan LLC. All rights reserved.
Table 1
The frequency of DNMT3A mutations in myeloproliferative neoplasms.
Author Screen MPN overall %
(No./total)
PV %
(No./total)
ET % (No./total) PMF % (No./total) Post-PV/ET MF %
(No./total)
Lin (this study) Exon 23 1 (1/130) 0 (0/35) 1 (1/91) 0 (0/4) d
Abdel-Wahab et al8 All coding 4 (3/68) d d 7 (3/46) 0 (0/22)
Stegelmann et al9 All coding 6 (5/80) 7 (2/30) 0 (0/30) 6 (1/16) 50 (2/4)
Rao et al17 Exon 23 2 (2/96) 3 (2/75) 0 (0/16) 0 (0/5) d
Brecqueville et al18 Exons 15e23 2 (2/129) 3 (1/33) 0 (0/56) 4 (1/25) 0 (0/15)
Lin et al19 All coding þ R882
HRM assay
0 (0/57) 0 (0/22) 0 (0/28) 0 (0/7) d
ET ¼ essential thrombocythemia; HRM ¼ high-resolution melting; PMF ¼ primary myeloﬁbrosis; PV ¼ polycythemia vera.
DNMT3A Mutation in Myeloproliferative Neoplasms 187MPL exon 10 [GenBank:NM_005373.2], IDH1 exon 4 [Gen-
Bank:NM_005896.2] and IDH2 exon 4 [GenBank:NM_002168.2]
were also subjected to nucleotide sequencing. The details of
mutational analysis are available upon request. In order to deter-
mine the lineage speciﬁcity of the DNMT3A R882H and JAK2 V617F
mutations in hematopoietic cells, we screened for these two mu-
tations in CD34þ, CD3þ, CD19þ, PBMC and PBGC populations
isolated by immunomagnetic beads separation methods (EasySep
system, STEMCELL Technologies, Vancouver, Canada) from the pa-
tient who harbored both DNMT3A and JAK2 mutations.Fig. 1. Cell lineageanalysisofDNMT3AR882Hand JAK2V617Fmutations in apatientwithessen
immunomagneticbeads separationmethods (EasySep system, STEMCELLTechnologies) and the
was analyzed in parallel as a reference control. The black asterisk denotes the mutation site. Th
(Blue Tractor Software Ltd, Llanfairfechan, Conwy, UK).3. Results and discussion
The frequencyof JAK2V617Fmutationwas69%, 69%and75% inPV,
ETandPMF, respectively.OnePVpatientwith thewild-type JAK2V617
codonharboredaK539Lmutation in JAK2exon1214.NoMPLor IDH1/2
mutation was detected in this cohort of patients. Nevertheless, one
somatic non-synonymous mutation in DNMT3A exon 23 was identi-
ﬁed in our cohort (Table 1). This is a heterozygous DNMT3A R882H
(2645 G>A) mutation in a patient with ET (P519), a 70-year-old man
who was diagnosed with the disease >10 years ago. Hence, thetial thrombocythemia. CD34þ, CD3þ, CD19þ, PBMCandPBGCpopulationswere isolatedby
ir genomicDNAwasanalyzedbynucleotide sequencing. Thepatient’s buccalDNAsample
e frequency of mutant alleles was determined DNA Dynamo sequence analysis software
H.-C. Lin et al.188frequencyofDNMT3Aexon23mutations inET is1%(1/91). Thepatient
is also positive for the JAK2 V617F mutation, but is wild-type forMPL
and IDH1/2. Both DNMT3A R882H and JAK2 V617F mutations were
somatic (Fig. 1). We also analyzed the genomic DNA extracted from
CD34þ, CD3þ, CD19þ, PBMC and PBGC populations isolated from this
patient. Both mutations were detected in the CD34þ (hematopoietic
progenitor cell)-, CD19þ (B lymphocyte)-, PBMC- and PBGC-enriched
fractions, but were not found in the CD3þ (T lymphocyte)-enriched
fraction (Fig. 1). Clonal assay was not successful, since the patient
had been treated with hydroxyurea. Clinically, the patient had never
had hemorrhagic or thrombotic complications, and his disease still
remained in a chronic phase, without obvious progression to myelo-
ﬁbrosis or AML during our study period.
DNMT3A mutations have been postulated to be one of the early
initiating events in the pathogenesis of AML15. DNMT3A R882H
mutation has been shown to result in reduced methyltransferase
activity and altered gene expression proﬁles4,16. Recently, the
DNMT3A R882C mutation was shown to predate the JAK2 V617F
mutation in a patient with PV17. Although there was a DNMT3A
missense variant N501S reported in ET9, our ﬁnding of DNMT3A
R882H mutation represented the ﬁrst conﬁrmed somatic DNMT3A
mutation in ET. The frequency of DNMT3A mutations in chronic
phase MPN ranges from 1% to 7% (Table 1), with the lowest in ET.
Unlike in AML5, the role ofDNMT3Amutations in disease severity or
progression to advanced phase in MPNs remains elusive, and our
ﬁnding of only one chronic phase ET patient harboring the DNMT3A
mutation did not reach any clinical signiﬁcance. One of the limi-
tations of this study is that only the exon 23 of DNMT3A was
screened for mutations and none was detected in PV or PMF. It is
not known at present whethermutations in other exons ofDNMT3A
exist in this cohort of patients. Another limitation of this study, is
that despite the detection of DNMT3A R882H in CD34þ and CD19þ
subpopulations, the lineage speciﬁcity of this mutation remains to
be determined, since the purity of magnetic bead-separated cell
subpopulations was not examined and, therefore, the possibility of
cross-lineage contamination cannot be completely excluded. In
conclusion, our ﬁndings suggest that DNMT3A mutation is not
prevalent in MPNs, and further study is needed to clarify its role in
the molecular pathogenesis of MPNs.Acknowledgments
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